{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:40:05Z","timestamp":1752237605585,"version":"3.41.2"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We report a case of a 19-year-old man with severe total parenteral nutrition\u2013dependent protein-losing enteropathy who was treated with upadacitinib. Treatment was complicated by renal failure requiring hemodialysis and severe diarrhea, which possibly hindered absorption.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring (TDM) and pharmacokinetic analyses were compared with published population pharmacokinetic data to determine the dose adjustments for each patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Based on TDM results, the dose was gradually increased from 30 mg once daily to 45 mg twice daily. Repeated sampling was performed to estimate the area under the curve (AUC)<jats:sub>6.5<\/jats:sub> (402.5 mcg*h\/L), which was higher than data reported in the literature (AUC<jats:sub>24<\/jats:sub> 525, SD \u00b1 123 mcg*h\/L dosing 30 mg extended release once daily). No AUC<jats:sub>24<\/jats:sub> could be calculated because of the absence of concentrations in the descending part of the concentration\u2013time curve. Clinical improvement was achieved at a higher dose, and no major signs and\/or symptoms of drug-related toxicity occurred.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Although TDM for Janus-kinase inhibitors is not yet a part of current clinical practice, in this case, the measurement of upadacitinib serum concentrations aided individualized dosing based on TDM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001326","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T08:37:18Z","timestamp":1743755838000},"page":"449-451","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Upadacitinib Optimization in a Patient With Protein-Losing Enteropathy Secondary to (Transient) Nonocclusive Mesenteric Ischemia, Idiopathic Myointimal Hyperplasia, and Hemodialysis"],"prefix":"10.1097","volume":"47","author":[{"given":"Johannes A.","family":"Kroes","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"},{"name":"Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Leeuwarden, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel D.","family":"Voskuil","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin H.","family":"Smeijsters","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Utrecht, Utrecht, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Krikke","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00ebl J.","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"},{"name":"Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijn C.","family":"Visschedijk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"R1-20250711","doi-asserted-by":"crossref","first-page":"e13403","DOI":"10.1097\/MD.0000000000013403","article-title":"Protein-losing enteropathy secondary to nonocclusive mesenteric ischemia: a case report","volume":"97","author":"Shima","year":"2018","journal-title":"Medicine"},{"key":"R2-20250711","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the effect of renal impairment on upadacitinib pharmacokinetics","volume":"59","author":"Mohamed","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"suppl_2","key":"R3-20250711","doi-asserted-by":"crossref","first-page":"S725","DOI":"10.1093\/ecco-jcc\/jjaa014","article-title":"Clinical pharmacology of Janus kinase inhibitors in inflammatory bowel disease","volume":"14","author":"Lefevre","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R4-20250711","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s40262-016-0419-y","article-title":"Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis","volume":"55","author":"Mohamed","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R5-20250711","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3748\/wjg.v23.i9.1513","article-title":"P-glycoprotein multidrug transporter in inflammatory bowel diseases: more questions than answers","volume":"23","author":"Cario","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R8-20250711","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","article-title":"Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication","volume":"59","author":"Mohamed","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R9-20250711","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40259-019-00366-1","article-title":"Factors influencing drug disposition of monoclonal antibodies in inflammatory bowel disease: implications for personalized medicine","volume":"33","author":"Lefevre","year":"2019","journal-title":"BioDrugs"},{"key":"R10-20250711","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11938-019-00222-9","article-title":"Advances in therapeutic drug monitoring for small-molecule and biologic therapies in inflammatory bowel disease","volume":"17","author":"Ma","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R11-20250711","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1053\/j.gastro.2020.03.089","article-title":"The nightmare monitoring of JAKinhibs","volume":"159","author":"Paul","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:00:52Z","timestamp":1752235252000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001326","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"2024-11-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}